Maximus Medicare Advantage Adverse-Determination Appeals Contract Lost to C2C Innovative Solutions (May 2026)
Open questionIn April-May 2026 Maximus lost the Medicare Advantage appeals contract to C2C Innovative Solutions ($116.5M, effective May 1, 2026 through April 30, 2030) — a documented counterexample to the idea that Maximus holds a single point of control over Medicare services, showing the government retains real alternatives. The loss is confirmed, with a watch left open: Maximus reclaiming the work within 24 months, or 2+ more such losses signaling broader deconcentration, would each reopen the question in a different direction.
The engine's record — word for word
Pre-registered Phoenix-Cycle falsification (BST III paper protocol, Report #86 May 8 2026). The original Maximus single-point-of-control thesis at the CMS layer was strictly tested by tracking ALL Medicare-related contract activity, not just the keystone 1-800-MEDICARE contact-center contract. **Empirical falsification:** April-May 2026, CMS announced that C2C Innovative Solutions won the contract for reviewing and processing appeals of Medicare Advantage adverse organization determinations and reconsiderations — REPLACING Maximus, which had previously held this work. **Engine framing:** this falsification proves that the federal layer retains operational alternatives in specific Medicare sub-domains. Maximus's CMS dominance is confined to the 1-800-MEDICARE + Healthcare.gov contact center keystone (where federal lawsuit forced 2024 CMS capitulation on early rebid) — it does NOT extend to every CMS contract category by default. The structural-insulation mechanism (H3 confirmed) operates through entitlement-mandatory-spending function, not through reflexive incumbent renewal. **Falsifiability discipline:** divergence resolves if Maximus reclaims the MA appeals contract or any equivalent CMS sub-contract within 24 months, or if the loss generalizes — i.e., if 2+ additional CMS sub-contracts also pivot to non-Maximus operators within the same window, signaling a broader CMS-deconcentration trajectory that would compress the H1-CMS-keystone-confirmation.
RESOLVED 2026-06-03 (deep-verify): CONFIRMED — CMS awarded the Part-C Independent Review Entity (MA adverse-determination appeals) contract to C2C Innovative Solutions ($116.5M; awarded Feb 26, effective May 1 2026, through Apr 30 2030), replacing Maximus. Forward watch retained: Maximus reclaim within 24mo, or 2+ additional CMS sub-contract losses, reopens. [AHA News / HME News / CMS award notice]
Walk this on the live map →